CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
Viciniumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00462488
NCT00462488Phase 2Completed
CompareCT.gov

Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Patients With Non-Invasive Urothelial Carcinoma in Situ (CIS) Previously Treated With Bacille Calmette-Guérin (BCG)

Sesen Bio, Inc.·interventional·Posted Apr 19, 2007·Updated May 12, 2020

In Brief

A Phase 2 clinical trial evaluating Vicinium for Urinary Bladder Cancer and 3 related conditions. Completed, enrolled 46 participants across 21 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous treatment with Bacille Calmette Guérin (BCG).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder Cancer, Bladder Cancer, Bladder Neoplasms, Bladder Tumors
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 19, 2007
Enrollment StartMar 1, 2007
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.2 years ago

Interventions

Viciniumdrug

Intravesical administration of Vicinium